PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Apontis Pharma AG (APPH.DE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

DE000A3CMGM5

Sector

Healthcare

Highlights

Market Cap

€92.65M

EPS (TTM)

-€0.83

Total Revenue (TTM)

€22.73M

Gross Profit (TTM)

€5.76M

EBITDA (TTM)

€2.04M

Year Range

€5.90 - €11.90

Target Price

€13.25

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of €10,000 in Apontis Pharma AG, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%0.00%20.00%40.00%60.00%SeptemberOctoberNovemberDecember2025February
41.80%
15.88%
APPH.DE (Apontis Pharma AG)
Benchmark (^GSPC)

Returns By Period

Apontis Pharma AG had a return of 6.97% year-to-date (YTD) and 62.88% in the last 12 months.


APPH.DE

YTD

6.97%

1M

2.38%

6M

41.45%

1Y

62.88%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

3.96%

1M

1.97%

6M

9.03%

1Y

22.16%

5Y*

12.60%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of APPH.DE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20255.97%6.97%
2024-6.11%41.70%0.63%29.87%3.15%0.94%-1.40%-17.22%-4.56%45.67%1.64%1.31%111.58%
20230.24%36.25%-3.57%8.33%-24.79%-4.77%-30.31%-9.59%-16.67%-22.73%16.76%19.65%-42.07%
2022-8.00%-17.93%-26.49%21.17%-0.74%-16.48%4.04%-14.14%-32.93%-6.59%53.85%-14.58%-59.00%
2021-5.60%1.41%16.99%10.95%13.30%-15.53%-10.31%0.00%6.67%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 82, APPH.DE is among the top 18% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of APPH.DE is 8282
Overall Rank
The Sharpe Ratio Rank of APPH.DE is 7979
Sharpe Ratio Rank
The Sortino Ratio Rank of APPH.DE is 8787
Sortino Ratio Rank
The Omega Ratio Rank of APPH.DE is 8888
Omega Ratio Rank
The Calmar Ratio Rank of APPH.DE is 7474
Calmar Ratio Rank
The Martin Ratio Rank of APPH.DE is 8080
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Apontis Pharma AG (APPH.DE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for APPH.DE, currently valued at 1.13, compared to the broader market-2.000.002.004.001.131.83
The chart of Sortino ratio for APPH.DE, currently valued at 2.61, compared to the broader market-6.00-4.00-2.000.002.004.006.002.612.47
The chart of Omega ratio for APPH.DE, currently valued at 1.37, compared to the broader market0.501.001.502.001.371.33
The chart of Calmar ratio for APPH.DE, currently valued at 0.83, compared to the broader market0.002.004.006.000.832.76
The chart of Martin ratio for APPH.DE, currently valued at 5.30, compared to the broader market-10.000.0010.0020.0030.005.3011.27
APPH.DE
^GSPC

The current Apontis Pharma AG Sharpe ratio is 1.13. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Apontis Pharma AG with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio1.001.502.002.503.00SeptemberOctoberNovemberDecember2025February
1.13
1.94
APPH.DE (Apontis Pharma AG)
Benchmark (^GSPC)

Dividends

Dividend History


Apontis Pharma AG doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-60.04%
-0.99%
APPH.DE (Apontis Pharma AG)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Apontis Pharma AG. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Apontis Pharma AG was 87.96%, occurring on Nov 14, 2023. The portfolio has not yet recovered.

The current Apontis Pharma AG drawdown is 60.04%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-87.96%Sep 30, 2021546Nov 14, 2023
-11.65%Aug 17, 20215Aug 23, 202123Sep 23, 202128
-11.58%May 17, 202122Jun 16, 202122Jul 16, 202144
-4.66%Aug 5, 20214Aug 10, 20213Aug 13, 20217
-4.42%Jul 19, 20213Jul 21, 20212Jul 23, 20215

Volatility

Volatility Chart

The current Apontis Pharma AG volatility is 11.86%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%SeptemberOctoberNovemberDecember2025February
11.86%
3.49%
APPH.DE (Apontis Pharma AG)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Apontis Pharma AG over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Apontis Pharma AG.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab